

CITATION REPORT

List of articles citing

The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide

DOI: 10.1136/bjo.2006.099598

British Journal of Ophthalmology, 2006, 90, 1344-9.

Source: <https://exaly.com/paper-pdf/41049380/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
438	Vascular endothelial growth factor biology: clinical implications for ocular treatments. <i>British Journal of Ophthalmology</i> , 2006 , 90, 1542-7	5.5	117
437	Is intravitreal bevacizumab (Avastin) safe?. <i>British Journal of Ophthalmology</i> , 2006 , 90, 1333-4	5.5	15
436	Intravitreal bevacizumab (Avastin) for the treatment of choroidal neovascularization in age-related macular degeneration: results from 118 cases. <i>British Journal of Ophthalmology</i> , 2007 , 91, 1716-7	5.5	17
435	VEGF inhibition: latest developments. 2007 , 2, 621-632		
434	Antiangiogenic therapy for normalization of atherosclerotic plaque vasculature: a potential strategy for plaque stabilization. 2007 , 4, 491-502		92
433	Bevacizumab for ophthalmic diseases. 2007 , 2, 369-378		2
432	Pharmacotherapies for diabetic retinopathy: present and future. 2007 , 2007, 52487		15
431	Histological findings of a choroidal neovascular membrane removed at the time of macular translocation in a patient previously treated with intravitreal bevacizumab treatment (Avastin). <i>British Journal of Ophthalmology</i> , 2007 , 91, 602-4	5.5	40
430	Efficacy of photodynamic therapy in the management of occult choroidal neovascularization associated with serous pigment epithelium detachment. 2007 , 221, 313-9		8
429	Endophthalmitis: classification and current management. 2007 , 2, 385-396		7
428	Intravitreal bevacizumab for macular edema due to occlusive vasculitis. 2007 , 22, 105-8		7
427	Our experience after 1765 intravitreal injections of bevacizumab: the importance of being part of a developing story. 2007 , 22, 109-25		33
426	Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). <i>British Journal of Ophthalmology</i> , 2007 , 91, 804-7	5.5	165
425	Tears of the retinal pigment epithelium: an old problem in a new era. 2007 , 27, 523-34		135
424	Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration. 2007 , 27, 541-51		130
423	Avastin versus Lucentis: ethical issues in treatment of age-related macular degeneration. 2007 , 27, 1163-5		12
422	Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. 2007 , 27, 439-44		139

421	Intravitreal Bevacizumab (Avastin) for the Treatment of Chorioretinal Vascular Diseases. 2007 , 5, 40-45	
420	Retinal pigment epithelium tears after intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. 2007 , 27, 535-40	54
419	Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study. 2007 , 114, 2190-6	113
418	Annual rates of arterial thromboembolic events in medicare neovascular age-related macular degeneration patients. 2007 , 114, 2174-8	60
417	Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin. 2007 , 143, 977-983	129
416	Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. 2007 , 143, 995-1002	197
415	Intravitreal bevacizumab therapy for neovascular age-related macular degeneration with large submacular hemorrhage. 2007 , 144, 886-892	79
414	A potential therapeutic strategy for capillary hemangioma with new anti-vascular endothelial growth factor (anti-VEGF) agents. 2007 , 69, 951	
413	Clinical update: new treatments for age-related macular degeneration. 2007 , 370, 204-206	117
412	Targeting vascular endothelial growth factor: a promising strategy for treating age-related macular degeneration. 2007 , 24, 643-62	41
411	Bevacizumab for neovascular ocular diseases. 2007 , 41, 614-25	137
410	Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema. 2007 , 21, 245-57	55
409	Intravitreal ranibizumab and bevacizumab: a review of risk. 2007 , 22, 201-4	53
408	Bevacizumab: a word of caution. 2007 , 42, 760-1	1
407	Short-term intraocular pressure changes after intravitreal injection of bevacizumab. 2007 , 42, 807-11	131
406	Retinal detachment with macular hole following combined photodynamic therapy and intravitreal bevacizumab injection. 2007 , 21, 185-7	19
405	Intravitreal Avastin for choroidal neovascularisation in pathological myopia: the controversy continues. <i>British Journal of Ophthalmology</i> , 2007 , 91, 128-30	5.5 8
404	Current awareness: Pharmacoepidemiology and drug safety. 2007 , 16, i-xii	

403	Acute endophthalmitis following intravitreal bevacizumab (Avastin) injection. 2007 , 21, 408-9	36
402	Intravitreal injection: balancing the risks. 2007 , 21, 313-6	5
401	Intravitreal VEGF-inhibitors: is Avastin a generic substitute for Lucentis?. 2007 , 85, 2-4	12
400	Treatment of choroidal neovascularization using intravitreal bevacizumab. 2007 , 85, 526-33	9
399	[Intravitreal bevacizumab versus verteporfin and intravitreal triamcinolone acetonide in patients with neovascular age-related macula degeneration]. 2007 , 104, 588-93	25
398	[Incidence of endophthalmitis after intravitreal Avastin injection with and without postoperative topical antibiotic application]. 2007 , 104, 952-7	30
397	Combination therapy for the treatment of ocular neovascularization. 2007 , 10, 141-8	94
396	Systemisches und intravitreales Bevacizumab (Avastin®) bei neovaskulärer altersbezogener Makuladegeneration. 2007 , 21, 154-159	1
395	Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). 2008 , 246, 81-7	336
394	Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity. 2007 , 245, 1727-30	119
393	Safety monitoring in bevacizumab (Avastin) treatment: retinal function assessed by psychophysical (visual fields, colour vision) and electrophysiological (ERG/EOG) tests in two subgroups of patients. 2008 , 28, 101-9	32
392	Vitritis in the contralateral uninjected eye following intravitreal bevacizumab (Avastin). 2008 , 28, 425-7	17
391	[Intravitreal anti-VEGF therapy with bevacizumab for neovascular AMD]. 2008 , 105, 538-43	4
390	[Intravitreal injection. Monitoring to avoid postoperative complications]. 2008 , 105, 143-55, 157	10
389	Endophthalmitisrate mit und ohne topische post-operative Antibiotikagabe nach intravitrealer Avastin-Injektion. 2008 , 22, 14-18	
388	Complications in patients after intravitreal injection of bevacizumab. 2008 , 86, 372-6	150
387	The evolving role of vascular endothelial growth factor inhibitors in the treatment of neovascular age-related macular degeneration. 2008 , 22, 761-7	36
386	Anti-VEGF therapy: comparison of current and future agents. 2008 , 22, 1330-6	77

385	Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6- and 9-month results. 2008 , 22, 82-6	60
384	Inhibitors of vascular endothelial growth factor (VEGF) in the management of neovascular age-related macular degeneration: a review of current practice. 2008 , 91, 427-37	47
383	Vascular endothelial growth factor in eye disease. 2008 , 27, 331-71	481
382	Age-related macular degeneration. 2008 , 358, 2606-17	1152
381	Drugs used in ocular treatment. 2008 , 30, 544-550	
380	Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. 2008 , 145, 249-256	158
379	Incidence of ocular hemorrhages in anticoagulated patients receiving repeated intravitreal injections. 2008 , 145, 386-7	4
378	Intravitreal bevacizumab for choroidal neovascularization in ocular histoplasmosis. 2008 , 145, 875-8	50
377	Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema. 2008 , 145, 854-61	149
376	The effect of topical bevacizumab on corneal neovascularization. 2008 , 115, e33-8	163
375	Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization. 2008 , 115, 1750-5, 1755.e1	130
374	Acute intraocular inflammation after intravitreal injections of bevacizumab for treatment of neovascular age-related macular degeneration. 2008 , 115, 1911-5	95
373	Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology. 2008 , 115, 1837-46	118
372	Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema. 2008 , 86, 800-5	39
371	Shall we use Avastin or Lucentis for ocular neovascularization?. 2008 , 86, 352-5	6
370	[Age-related macular degeneration and risk of stroke]. 2008 , 31, 111-25	0
369	[Age-related macular degeneration and antivascular endothelial growth factor: a review]. 2008 , 31, 94-110	1
368	Intravitreal bevacizumab for the treatment of choroidal neovascularization associated with pathological myopia. 2008 , 43, 576-80	15

367	Pharmacotherapy for the treatment of choroidal neovascularization due to age-related macular degeneration. 2008 , 48, 61-78		32
366	Bevacizumab sterility in multiple doses from a single-use vial. 2008 , 42, 1425-8		19
365	Use of thalidomide to diminish growth velocity in a life-threatening congenital intracranial hemangioma. 2008 , 2, 125-9		16
364	Intravitreal bevacizumab and triamcinolone acetonide combination therapy for exudative neovascular age-related macular degeneration: short-term optical coherence tomography results. 2008 , 24, 15-24		15
363	Verteporfin photodynamic therapy in the age of antiangiogenic therapy. 2008 , 3, 365-383		1
362	Needle Bleb Revision With Bevacizumab. 2008 , 6, 111-113		
361	Reply. 2008 , 28, 1557-1559		
360	Subretinal hemorrhage after lens-sparing vitrectomy in infants born at or under 24 weeks gestation. 2008 , 28, S69-74		4
359	Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection. 2008 , 28, 564-7		128
358	Surveillance for potential adverse events associated with the use of intravitreal bevacizumab for retinal and choroidal vascular disease. 2008 , 28, 1151-8		57
357	Bacterial contamination of ocular surface and needles in patients undergoing intravitreal injections. 2008 , 28, 877-83		65
356	Effects of macular ischemia on the outcome of intravitreal bevacizumab therapy for diabetic macular edema. 2008 , 28, 957-63		90
355	Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. 2008 , 28, 1395-9		174
354	Intraocular bevacizumab for iris neovascularization in a silicone oil-filled eye. 2008 , 2, 253-5		2
353	Subconjunctival bevacizumab injection for corneal neovascularization. 2008 , 27, 142-7		110
352	Effect of subconjunctival bevacizumab (Avastin) on experimental corneal neovascularization in guinea pigs. 2008 , 27, 357-62		45
351	Treatment of age-related macular degeneration: focus on ranibizumab. <i>Clinical Ophthalmology</i> , 2008 , 2, 1-14	2.5	21
350	Current and emerging therapies for the treatment of age-related macular degeneration. <i>Clinical Ophthalmology</i> , 2008 , 2, 377-88	2.5	35

349	Pegaptanib sodium for neovascular age-related macular degeneration: clinical experience in the UK. <i>Clinical Ophthalmology</i> , 2008 , 2, 347-54	2.5	3
348	Short-term Safety and Efficacy of Intravitreal Bavacizumab Injection. 2009 , 50, 219		4
347	Effects and Prognostic Factors of Intravitreal Bevacizumab Injection on Choroidal Neovascularization from Age-Related Macular Degeneration. 2009 , 50, 202		6
346	Intravitreal bevacizumab for the treatment of neovascular glaucoma associated with central retinal artery occlusion. 2009 , 23, 215-8		8
345	Bevacizumab for ocular neovascular diseases: a systematic review. 2009 , 127, 84-91		11
344	Serous retinal detachment following combined photodynamic therapy and intravitreal bevacizumab injection. 2009 , 23, 124-6		
343	Emerging therapies for diabetic macular edema. 2009 , 4, 163-171		1
342	Pharmacotherapy for diabetic retinopathy. 2009 , 10, 1123-31		10
341	Endophthalmitis after intravitreal injections. 2009 , 10, 2119-26		31
340	Microlaryngoscopic and office-based injection of bevacizumab (Avastin) to enhance 532-nm pulsed KTP laser treatment of glottal papillomatosis. 2009 , 201, 1-13		33
339	Bevacizumab (avastin) in ocular processes other than choroidal neovascularization. 2009 , 17, 109-17		5
338	Effects of intravitreal bevacizumab (Avastin) therapy on retrobulbar blood flow parameters in patients with neovascular age-related macular degeneration. 2010 , 38, 66-70		16
337	A systematic review on the effect of bevacizumab in exudative age-related macular degeneration. 2009 , 247, 1-11		74
336	Wirksamkeit und Sicherheit der transskleralen Anti-VEGF-Eingabe. 2009 , 23, 249-255		1
335	Intensified monitoring of circadian blood pressure and heart rate before and after intravitreal injection of bevacizumab: preliminary findings of a pilot study. 2009 , 29, 213-24		18
334	Acute endophthalmitis caused by <i>Staphylococcus lugdunensis</i> after intravitreal bevacizumab (Avastin) injection. 2009 , 29, 411-3		8
333	Intravitreal bevacizumab (avastin) for subfoveal neovascular age-related macular degeneration. 2009 , 29, 349-57		24
332	Intracameral bevacizumab for rubeotic glaucoma secondary to retinal vein occlusion. 2009 , 29, 537-9		7

331	[Intravitreal bevacizumab for choroidal neovascularization due to pathological myopia]. 2009 , 106, 527-30	9
330	[Retinochoroidopathy after intravitreal anti-VEGF treatment]. 2009 , 106, 729-34	2
329	Bevacizumab: a new hope?. 2009 , 23, 1755-7	
328	Management of extensive subfoveal haemorrhage secondary to neovascular age-related macular degeneration. 2009 , 23, 1404-10	46
327	The effect of intravitreal bevacizumab (avastin) administration on systemic hypertension. 2009 , 23, 1714-8	46
326	Randomised clinical trial of intravitreal Avastin vs photodynamic therapy and intravitreal triamcinolone: long-term results. 2009 , 23, 2223-7	35
325	Serous pigment epithelial detachment in age-related macular degeneration: comparison of different treatments. 2009 , 23, 2163-8	57
324	Incidence and management of acute endophthalmitis after intravitreal bevacizumab (Avastin) injection. 2009 , 23, 2187-93	59
323	Bevacizumab (Avastin) for the treatment of ocular disease. 2009 , 54, 372-400	114
322	Position paper: the need for head-to-head studies comparing Avastin versus Lucentis. 2009 , 54, 705-7	3
321	Microincision vitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment. 2009 , 116, 927-38	136
320	Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration. 2009 , 116, 1740-7	112
319	Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results. 2009 , 147, 94-100.e1	136
318	Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results. 2009 , 147, 84-93.e1	97
317	Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: the second year of a prospective study. 2009 , 148, 59-65.e1	67
316	Intravitreal bevacizumab vs sub-tenon triamcinolone acetonide for choroidal neovascularization attributable to pathologic myopia. 2009 , 148, 591-596.e1	10
315	Safety implications of vascular endothelial growth factor blockade for subjects receiving intravitreal anti-vascular endothelial growth factor therapies. 2009 , 148, 647-56	77
314	Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial. 2009 , 148, 875-82.e1	56

313	Off-label use of bevacizumab for the treatment of age-related macular degeneration: what is the evidence?. 2009 , 26, 295-320	19
312	Pterygia: pathogenesis and the role of subconjunctival bevacizumab in treatment. 2009 , 24, 130-4	42
311	Anterior chamber bevacizumab for rubeotic glaucoma secondary to retinal artery occlusion?. 2009 , 3, 122	
310	Therapeutic efficacy of intravitreal bevacizumab on posterior uveitis complicated by neovascularization. 2009 , 87, 349-52	37
309	Transient global amnesia following intravitreal injection of bevacizumab. 2009 , 87, 570	4
308	Effect of intravitreal bevacizumab (Avastin) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month results. 2010 , 88, 594-600	22
307	[Intravitreal bevacizumab for treatment of neovascular glaucoma. Report of 20 cases]. 2009 , 32, 652-63	10
306	[Subretinal hemorrhage after intravitreal injection of anti-VEGF for age-related macular degeneration: a retrospective study]. 2009 , 32, 309-13	9
305	The article by Fintak et al on the incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. 2009 , 29, 720-1; author reply 721-2	3
304	Intravitreal injection of therapeutic agents. 2009 , 29, 875-912	173
303	Vascular events in patients with age-related macular degeneration treated with intraocular bevacizumab. 2009 , 29, 1404-8	10
302	Bevacizumab for the Treatment of Corneal Neovascularization. 2009 , 28, S26-S30	1
301	Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. 2009 , 20, 158-65	91
300	Anterior ischemic optic neuropathy after intravitreal injection of bevacizumab. 2009 , 29, 160-1	28
299	Efficacy of 1.25 MG versus 2.5 MG intravitreal bevacizumab for diabetic macular edema: six-month results of a randomized controlled trial. 2009 , 29, 292-9	72
298	Intravitreal injection of 2.5 mg versus 1.25 mg bevacizumab (Avastin) for treatment of CNV associated with AMD. 2009 , 29, 319-24	45
297	Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2,000 injections. 2009 , 29, 313-8	94
296	Anti-VEGF therapy in proliferative diabetic retinopathy. <i>International Ophthalmology Clinics</i> , 2009 , 49, 95-107	1.7 28

295	The effect of different doses of intracameral bevacizumab on surgical outcomes of trabeculectomy for neovascular glaucoma. 2009 , 19, 435-41	28
294	Rituximab for intraocular lymphoma. 2009 , 29, 129-32	57
293	Visual outcomes and growth factor changes of two dosages of intravitreal bevacizumab for neovascular age-related macular degeneration: a randomized, controlled trial. 2009 , 29, 1218-26	21
292	Nouveaux traitements de la dégénérescence maculaire liée à l'âge. 2009 , 6, 1-16	
291	A prospective study of blood pressure and intraocular pressure changes in hypertensive and nonhypertensive patients after intravitreal bevacizumab injection. 2009 , 29, 1409-17	26
290	Toxic vitreitis outbreak after intravitreal injection. 2010 , 30, 332-8	40
289	Incidence of hemorrhagic complications after intravitreal bevacizumab (avastin) or ranibizumab (lucentis) injections on systemically anticoagulated patients. 2010 , 30, 1386-9	25
288	High-molecular-weight aggregates in repackaged bevacizumab. 2010 , 30, 887-92	101
287	Sterile endophthalmitis after intravitreal injection of bevacizumab obtained from a single batch. 2010 , 30, 485-90	50
286	The results of intravitreal bevacizumab injections for persistent neovascularizations in proliferative diabetic retinopathy after photocoagulation therapy. 2010 , 30, 570-7	21
285	Optical coherence tomography-measured pigment epithelial detachment height as a predictor for retinal pigment epithelial tears associated with intravitreal bevacizumab injections. 2010 , 30, 203-11	87
284	Intravitreal bevacizumab during pregnancy. 2010 , 30, 1405-11	71
283	Characterization of sterile intraocular inflammatory responses after intravitreal bevacizumab injection. 2010 , 30, 1432-40	46
282	[Effect of intravitreal bevacizumab on pigment epithelial detachment in occult choroidal neovascularization]. 2010 , 107, 827-30	3
281	A systematic review on the effect of bevacizumab in exudative age-related macular degeneration: a response to a letter to the editor by Schmucker et al.. 2010 , 248, 453-454	78
280	A systematic review on the effect of bevacizumab in exudative age-related macular degeneration. 2010 , 248, 451-2; author reply 453-4	4
279	Vascular endothelial growth factor concentrations in aqueous humor before and after subconjunctival injection of bevacizumab for neovascular glaucoma. 2010 , 54, 242-4	6
278	Intravitreal therapy for neovascular age-related macular degeneration and inter-individual variations in vitreous pharmacokinetics. 2010 , 29, 466-75	59

277	Retrospective study of an as required dosing regimen of intravitreal bevacizumab in neovascular age-related macular degeneration in an Australian population. 2010 , 38, 659-63		6
276	Bilateral intraocular inflammation after intravitreal bevacizumab in Behcet's disease. 2010 , 24, 735		7
275	Intravitreal bevacizumab (Avastin) for age-related macular degeneration: a critical analysis of literature. 2010 , 24, 816-24		35
274	<i>Serratia marcescens</i> endophthalmitis associated with intravitreal injections of bevacizumab. 2010 , 24, 226-32		31
273	Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial. 2010 , 24, 1708-15		57
272	Blood pressure changes after intravitreal bevacizumab in patients grouped by ocular pathology. 2010 , 24, 1320-4		4
271	Intravitreal Bevacizumab Treatment of Macular Edema in Central Retinal Vein Occlusion. 2010 , 51, 707		6
270	Farmacos anti-VEGF en el edema macular diabético. 2010 , 107-113		
269	Sequential anterior ischemic optic neuropathy and central retinal artery and vein occlusion after ranibizumab for diabetic macular edema. 2010 , 20, 1076-8		16
268	Macular Hole Following Intravitreal Ranibizumab Injections for Choroidal Neovascularization. 2010 , 51, 774		2
267	Antiangiogenic drugs in the management of ocular diseases: Focus on antivascular endothelial growth factor. <i>Clinical Ophthalmology</i> , 2010 , 4, 275-83	2.5	14
266	Argon Laser Photocoagulation Combined With Subconjunctival and Intravitreal Bevacizumab Injections for a Retrocorneal Neovascular Membrane. 2010 , 51, 292		
265	The Short-Term Efficacy of Intravitreal Ranibizumab in the Treatment of Diabetic Macular Edema. 2010 , 51, 1453		
264	Is monthly retreatment with intravitreal bevacizumab (Avastin) necessary in neovascular age-related macular degeneration?. <i>Clinical Ophthalmology</i> , 2010 , 4, 307-14	2.5	5
263	Comparative Review of Ranibizumab versus Bevacizumab in the Treatment of Neovascular Age-related Macular Degeneration. 2010 , 2, CMT.S2226		
262	Rebound neovascularization during bevacizumab therapy. 2010 , 4, 216-9		1
261	Posterior reversible encephalopathy syndrome after intravitreal bevacizumab injection in patient with choroidal neovascular membrane secondary to age-related maculopathy. 2010 , 26, 301-3		12
260	Bevacizumab for neovascular age-related macular degeneration (ABC trial): multicenter randomized double-masked study. 2010 , 3, 747-52		5

259	Isolated sixth nerve palsy after intravitreal bevacizumab injection. 2010 , 18, 18-20	9
258	Incidence of damage to the crystalline lens during intravitreal injections. 2010 , 26, 491-5	44
257	Neovascular age-related macular degeneration and the risk of stroke: a 5-year population-based follow-up study. 2010 , 41, 613-7	50
256	Outcome of intravitreal bevacizumab for idiopathic choroidal neovascularization in a Chinese population. 2010 , 45, 381-385	11
255	Incidence and characteristics of acute intraocular inflammation after intravitreal injection of bevacizumab: a retrospective cohort study. 2010 , 45, 239-42	27
254	Effect of systemic medications on onset and progression of diabetic retinopathy. 2010 , 6, 494-508	34
253	Severe intraocular inflammation after intravitreal injection of bevacizumab. 2010 , 117, 512-6, 516.e1-2	55
252	Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab—a randomized controlled trial. 2010 , 149, 458-64.e1	88
251	Retinal artery occlusion following intravitreal anti-VEGF therapy. 2010 , 88, 263-6	42
250	Retinal vascular events after intravitreal bevacizumab. 2010 , 88, 730-5	36
249	Visual improvement in central retinal vein occlusion (CRVO) following intravitreal injections of bevacizumab (Avastin®). 2010 , 88, 836-41	11
248	Intravitreal triamcinolone, bevacizumab and pegaptanib for occult choroidal neovascularization. 2010 , 88, e305-10	6
247	Identifying systemic safety signals following intravitreal bevacizumab: systematic review of the literature and the Canadian Adverse Drug Reaction Database. 2010 , 45, 231-8	25
246	Choroidal detachment after an uneventful intravitreal injection. 2010 , 26, 305-7	2
245	Severe corneal changes following intravitreal injection of bevacizumab. 2010 , 18, 268-74	16
244	Cost effectiveness of treatments for wet age-related macular degeneration. 2011 , 29, 107-31	37
243	Toxicological considerations for intravitreal drugs. 2011 , 7, 1021-34	13
242	Ocular treatment of diabetic macular edema in Canada: where are we going?. 2011 , 46, 221-4	1

241	ACV isquémico asociado a inyección intravítrea de bevacizumab. 2011 , 3, 64-67		
240	A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab. 2011 , 27, 1465-75		76
239	Arterial thromboembolic events in patients with exudative age-related macular degeneration treated with intravitreal bevacizumab or ranibizumab. 2011 , 225, 211-21		46
238	Management of Neovascular AMD. 2011 , 79-98		
237	Bevacizumab and neovascular age related macular degeneration: pathogenesis and treatment. 2011 , 26, 69-76		21
236	Endophthalmitis following intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration. 2011 , 26, 139-48		18
235	Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 medicare fee-for-service part B claims file. 2011 , 151, 887-895.e1		107
234	[Assessment of the effectiveness and safety of ranibizumab in neovascular age-related macular degeneration]. 2011 , 136, 471-7		
233	Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. 2011 , 56, 95-113		209
232	Efficacy of 12-month treatment of neovascular age-related macular degeneration with intravitreal bevacizumab based on individually determined injection strategies after three consecutive monthly injections. 2011 , 89, 647-53		15
231	Incidence of rhegmatogenous retinal detachments after intravitreal anti-vascular endothelial factor injections. 2011 , 89, 70-5		74
230	The Short-Term Efficacy of Intravitreal Ranibizumab for Macular Edema in Central Retinal Vein Occlusion. 2011 , 52, 1048		3
229	Acute anterior uveitis following intravitreal bevacizumab but not subsequent ranibizumab. <i>Clinical Ophthalmology</i> , 2011 , 5, 1659-62	2.5	2
228	Adverse skin reactions following intravitreal bevacizumab injection. <i>BMJ Case Reports</i> , 2011 , 2011,	0.9	2
227	Intravitreal bevacizumab for macular edema due to branch retinal vein occlusion: 12-month results. <i>Clinical Ophthalmology</i> , 2011 , 5, 745-9	2.5	17
226	Intravitreal bevacizumab in central retinal vein occlusion: 18-month results of a prospective clinical trial. 2011 , 21, 789-95		18
225	Lasting controversy on ranibizumab and bevacizumab. 2011 , 1, 395-402		27
224	Management of neovascular age-related macular degeneration in clinical practice: initiation, maintenance, and discontinuation of therapy. 2011 , 2011, 752543		3

223	Assessment of anterior chamber inflammation after intravitreal bevacizumab injection in different ocular exudative diseases. 2011 , 21, 156-61	10
222	Hyphema after intravitreal injection of ranibizumab or bevacizumab. 2011 , 5, 87-90	0
221	Treatments for corneal neovascularization: a review. 2011 , 30, 927-38	88
220	One-year outcomes of less frequent bevacizumab in age-related macular degeneration. 2011 , 31, 645-53	12
219	Ranibizumab for the treatment of exudative age-related macular degeneration associated with retinal pigment epithelial tear. 2011 , 31, 1083-8	8
218	Endophthalmitis after intravitreal vascular [corrected] endothelial growth factor antagonists: a six-year experience at a university referral center. 2011 , 31, 662-8	151
217	Different dosing of intravitreal bevacizumab for choroidal neovascularization because of pathologic myopia. 2011 , 31, 880-6	29
216	Endophthalmitis after intravitreal injection: the importance of viridans streptococci. 2011 , 31, 1525-33	95
215	Efficacy and safety of intravitreal bevacizumab compared with intravitreal and posterior sub-tenon triamcinolone acetonide for treatment of uveitic cystoid macular edema. 2011 , 31, 111-8	56
214	A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections. 2011 , 31, 1449-69	112
213	Local injection of bevacizumab (Avastin) and angiolytic KTP laser treatment of recurrent respiratory papillomatosis of the vocal folds: a prospective study. 2011 , 120, 627-34	72
212	Reducing oral flora contamination of intravitreal injections with face mask or silence. 2012 , 32, 473-6	74
211	Pharmacokinetics of pars plana intravitreal injections versus microcannula suprachoroidal injections of bevacizumab in a porcine model. 2011 , 52, 4749-56	76
210	Meta-analysis and review on the effect of bevacizumab in diabetic macular edema. 2011 , 249, 15-27	38
209	The rate of myocardial infarction events among patients with age-related macular degeneration: a population-based study. 2011 , 249, 179-82	10
208	Intravitreal bevacizumab in retinopathy of prematurity: an interventional case series. 2011 , 249, 1295-301	13
207	An unusual case of allopurinol hypersensitivity syndrome potentiated by intravitreal bevacizumab. 2011 , 67, 537-8	2
206	Evaluation of the incidence of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor. 2011 , 226, 145-50	32

205	Clinical review: Update on treatment of inflammatory macular edema. 2011 , 19, 75-83		34
204	Intravitreal injection of 2.5 mg bevacizumab for treatment of myopic choroidal neovascularization in treatment-naive cases: a 2-year follow-up. 2011 , 27, 395-400		14
203	Macular hole formation after intravitreal bevacizumab administration in a patient with myopic choroidal neovascularization. 2011 , 5, 149-52		12
202	Macular edema formation and deterioration of retinal function after intravitreal bevacizumab injection for proliferative diabetic retinopathy. 2011 , 2, 314-8		0
201	Preoperative visual acuity among cataract surgery patients and countriesPstate of development: a global study. 2011 , 89, 749-56		32
200	Intravitreal injection technique. 2011 , 26, 104-13		22
199	Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration. <i>Indian Journal of Ophthalmology</i> , 2011 , 59, 191-6	1.6	52
198	Sterile endophthalmitis after intravitreal injections. 2012 , 2012, 928123		40
197	The relative clinical effectiveness of ranibizumab and bevacizumab in diabetic macular oedema: an indirect comparison in a systematic review. 2012 , 345, e5182		49
196	Effect on anterior chamber bevacizumab injection combined with seton implantation in treatment of rubeosis iridis in neovascular glaucoma. 2012 , 31, 124-7		11
195	Should we be concerned about antibiotic resistance when using intravitreal injections?. 2012 , 7, 393-395		
194	Clinical and electrophysiologic outcome in patients with neovascular glaucoma treated with and without bevacizumab. 2012 , 22, 563-74		23
193	Effect of intravitreal bevacizumab on retrobulbar blood flow in injected and uninjected fellow eyes of patients with neovascular age-related macular degeneration. 2012 , 32, 967-71		27
192	Anti-VEGF therapy with bevacizumab for anterior segment eye disease. 2012 , 31, 322-34		24
191	Response to Replacing ranibizumab with bevacizumab on the Pharmaceutical Benefits Scheme: where does the current evidence leave us?. 2012 , 95, 541-3		1
190	[Conspicuous crystalline lens foreign body after intravitreal injection]. 2012 , 109, 1119-21		18
189	Bevacizumab versus ranibizumab in the treatment of exudative age-related macular degeneration: a retrospective study of 58 patients. 2012 , 35, 661-6		7
188	The expanding role of vascular endothelial growth factor inhibitors in ophthalmology. 2012 , 87, 77-88		129

187	Canadian expert consensus: optimal treatment of neovascular age-related macular degeneration. 2012 , 47, 227-35		18
186	Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections. 2012 , 119, 1609-14		154
185	Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. 2012 , 153, 327-333.e1		233
184	Novel adverse events of bevacizumab in the US FDA adverse event reporting system database: a disproportionality analysis. 2012 , 35, 507-18		31
183	Corneal neovascularization: an anti-VEGF therapy review. 2012 , 57, 415-29		244
182	Choroidal neovascularization in pathological myopia. 2012 , 31, 495-525		167
181	Long-term stability of bevacizumab repackaged in 1mL polypropylene syringes for intravitreal administration. 2012 , 70, 139-54		33
180	Comparison of systemic adverse events associated with intravitreal anti-VEGF injection: ranibizumab versus bevacizumab. 2012 , 27, 1580-5		16
179	Insight into 144 patients with ocular vascular events during VEGF antagonist injections. <i>Clinical Ophthalmology</i> , 2012 , 6, 343-63	2.5	20
178	Anterior uveitis after treatment of age-related macular degeneration with ranibizumab and bevacizumab: uncommon complication. <i>Clinical Ophthalmology</i> , 2012 , 6, 1201-5	2.5	11
177	Retinopathy of prematurity promising newer modalities of treatment. 2012 , 49, 139-43		10
176	Intravitreal bevacizumab as an adjunct to vitrectomy in advanced Eales Disease. 2012 , 2, 105-8		5
175	Adverse events associated with intraocular injections of bevacizumab in eyes with neovascular glaucoma. 2012 , 250, 603-10		21
174	Intravitreal bevacizumab alone versus in combination with photodynamic therapy for the treatment of neovascular maculopathy in patients aged 50 years or older: 1-year results of a prospective clinical study. 2012 , 90, 61-7		30
173	Osteonecrosis after administration of intravitreal bevacizumab. 2012 , 70, 632-5		32
172	Are monoclonal antibodies a safe treatment for cancer during pregnancy?. 2013 , 5, 733-41		29
171	Light-activated, in situ forming gel for sustained suprachoroidal delivery of bevacizumab. 2013 , 10, 2858-67		69
170	Drug-induced uveitis. 2013 , 3, 43		51

169	Acute bacterial endophthalmitis after intravitreal bevacizumab injection: Case report and literature review. 2013 , 27, 55-7	4
168	Acute stroke after intravitreal bevacizumab to treat choroidal neovascularization due to angioid streaks in pseudoxanthoma elasticum : a severe systemic adverse event after an off-label procedure. 2013 , 33, 181-3	7
167	Tower microneedle minimizes vitreal reflux in intravitreal injection. 2013 , 15, 841-8	11
166	Minimizing the endophthalmitis rate following intravitreal injections using 0.25% povidone-iodine irrigation and surgical mask. 2013 , 251, 1885-90	58
165	The impact of short-term topical gatifloxacin and moxifloxacin on bacterial injection after hypodermic needle passage through human conjunctiva. 2013 , 29, 450-5	1
164	Shanghai eye treatment outbreak: bevacizumab therapy for AMD in China. 2013 , 96, 106-8	5
163	Comparison of intravitreal triamcinolone acetonide with intravitreal bevacizumab for treatment of diabetic macular edema: a meta-analysis. 2013 , 38, 578-87	14
162	Unilateral branch retinal arterial occlusion following administration of bevacizumab for branch retinal vein occlusion. 2013 , 33, 549-52	5
161	Intravitreal bevacizumab may increase diabetic macular edema in eyes with attached posterior vitreous. 2013 , 4, 7-10	4
160	Subconjunctival bevacizumab injection in glaucoma filtering surgery: a case control series. 2013 , 2013, 384134	4
159	Bacterial contamination of needles used for intravitreal injections: comparison between 27-gauge and 30-gauge needles. 2013 , 21, 366-70	10
158	Combined therapy for diabetic macular edema. 2013 , 20, 315-20	5
157	Drug-induced uveitis. 2013 , 24, 589-97	26
156	Current treatments in diabetic macular oedema: systematic review and meta-analysis. 2013 , 3,	77
155	Evaluation of RGD peptide hydrogel in the posterior segment of the rabbit eye. 2013 , 24, 1185-97	11
154	Meta-analysis of the effect of intravitreal bevacizumab versus intravitreal triamcinolone acetonide in central retinal vein occlusion. 2013 , 29, 826-31	4
153	Acute endophthalmitis after intravitreal injection and preventive effect of preoperative topical antibiotics. 2013 , 29, 900-5	17
152	Acute vision loss associated with retinal circulatory disturbances after intravitreal injection of bevacizumab. 2013 , 29, 79-83	3

151	Conjunctival pyogenic granuloma associated with intravitreal bevacizumab injection. 2013 , 7, 291-3		2
150	Sudden visual loss in the untreated eye of a patient with neovascular glaucoma following an intravitreal bevacizumab injection: A case report. 2013 , 6, 445-447		0
149	Thrombocytopenia after Intravitreal Bevacizumab Injection for Macular Edema in Branch Retinal Vein Occlusion. 2013 , 54, 1788		1
148	Changes in the foveal microstructure after intravitreal bevacizumab application in patients with retinal vascular disease. <i>Clinical Ophthalmology</i> , 2013 , 7, 173-8	2.5	26
147	Regression of iris neovascularization after subconjunctival injection of bevacizumab. 2013 , 27, 299-303		7
146	Effects of Vitrectomy on Recurrent Macular Edema due to Branch Retinal Vein Occlusion after Intravitreal Injection of Bevacizumab. 2013 , 2013, 415974		8
145	Macular Hole after Single Intravitreal Injection of Ranibizumab in a Patient with Age-Related Macular Degeneration. 2013 , 54, 1130		2
144	Imaging of sub-retinal pigment epithelial linear structures in patients with age-related macular degeneration. 2014 , 24, 744-50		1
143	Immediate effect of intravitreal injection of bevacizumab on intraocular pressure. <i>Clinical Ophthalmology</i> , 2014 , 8, 1383-8	2.5	14
142	Evaluation of intraocular pressure elevation after multiple injections of intravitreal ranibizumab. <i>Clinical Ophthalmology</i> , 2014 , 8, 743-7	2.5	6
141	Short-term intraocular pressure changes after intravitreal injection of bevacizumab in diabetic retinopathy patients. <i>Clinical Ophthalmology</i> , 2014 , 8, 599-604	2.5	9
140	Intravitreal injection of ranibizumab using a pro re nata regimen for age-related macular degeneration and vision-related quality of life. <i>Clinical Ophthalmology</i> , 2014 , 8, 1711-6	2.5	11
139	Changes in the Retinal Nerve Fiber Layer after Intravitreal Injections of Bevacizumab in Glaucoma Patients. 2014 , 55, 693		4
138	No cases of endophthalmitis after 20,293 intravitreal injections in an operating room setting. 2014 , 34, 951-7		47
137	Does intravitreal injections of bevacizumab for age-related macular degeneration affect long-term intraocular pressure?. 2014 , 23, 446-8		10
136	[Relationship between intravitreal anti-VEGF therapy and subretinal hemorrhage in patients with exudative age-related macular degeneration]. 2014 , 37, 195-201		5
135	Impact of intravitreal triamcinolone acetonide versus intravitreal bevacizumab on retrobulbar hemodynamic in patients with diabetic macular edema. 2014 , 33, 49-53		10
134	Correlation between aqueous flare and chorioretinal neovascularization in age-related macular degeneration following intravitreal bevacizumab injections. 2014 , 37, 30-5		1

133	Complications of intravitreal injections in patients with diabetes. 2014 , 29, 276-89	32
132	[Safety and efficacy of subconjunctival triamcinolone injections in the management of uveitic macular edema: retrospective study of thirty-one cases]. 2014 , 37, 599-604	5
131	A safety evaluation of ranibizumab in the treatment of age-related macular degeneration. 2014 , 13, 1259-70	12
130	Blockade of the VEGF isoforms in inflammatory corneal hemangiogenesis and lymphangiogenesis. 2014 , 252, 943-9	12
129	Value of eye movement examination in aiding precise localization in stroke. 2014 , 45, e157-9	2
128	Survey of intravitreal injection techniques and treatment protocols among retina specialists in Canada. 2014 , 49, 261-6	30
127	Ocular Infection: Endophthalmitis. 2016 , 55, 176-88	19
126	Effect of intravitreal bevacizumab on retrobulbar blood flow of patients with diabetic macular edema. 2015 , 25, 539-45	3
125	SUSTAINED ELEVATION OF INTRAOCULAR PRESSURE AFTER INTRAVITREAL ANTI-VEGF AGENTS: What Is the Evidence?. 2015 , 35, 841-58	53
124	IDENTIFICATION OF FLUID ON OPTICAL COHERENCE TOMOGRAPHY BY TREATING OPHTHALMOLOGISTS VERSUS A READING CENTER IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENTS TRIALS. 2015 , 35, 1303-14	40
123	Intravitreal aflibercept after bilateral bevacizumab-induced iritis. 2015 , 92, e97-e105	1
122	INCIDENCE OF SUSTAINED OCULAR HYPERTENSION USING PREPACKAGED VERSUS FRESHLY PREPARED INTRAVITREAL BEVACIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. 2015 , 35, 1992-2000	4
121	Ocular inflammation associated with antivascular endothelial growth factor treatment. 2015 , 26, 184-7	10
120	Occurrence of macular hematoma after ranibizumab treatment for age-related macular degeneration. 2015 , 25, 163-7	2
119	Anti-VEGF treatment for myopic choroid neovascularization: from molecular characterization to update on clinical application. 2015 , 9, 3413-21	20
118	Management of pseudophakic cystoid macular edema. 2015 , 60, 123-37	72
117	Central Retinal Artery Occlusion. 2015 , 239-305	1
116	Frequency and characteristics of intraocular inflammation after aflibercept injection. 2015 , 35, 681-6	21

115	Safety and pharmacodynamics of suprachoroidal injection of triamcinolone acetonide as a controlled ocular drug release model. 2015 , 203, 109-17		57
114	Different Effects of Ranibizumab and Bevacizumab on Platelet Activation Profile. 2015 , 234, 195-210		8
113	Local and systemic complications after intravitreal administration of anti-vascular endothelial growth factor agents in the treatment of different ocular diseases: a five-year retrospective study. 2015 , 30, 129-35		19
112	Intravitreal Bevacizumab for Treatment of Central Serous Chorioretinopathy. <i>Journal of Ophthalmic and Vision Research</i> , 2016 , 11, 61-5	1.2	12
111	Photopsias during Systemic Bevacizumab Therapy. 2016 , 2016, 1926178		2
110	Systemic safety of intravitreal anti-vascular endothelial growth factor agents in age-related macular degeneration. 2016 , 27, 224-43		9
109	Long-Term Effect of Anti-VEGF Agents on Intraocular Pressure in Age-Related Macular Degeneration. 2016 , 56, 30-4		7
108	Intravitreal vascular endothelial growth factor (VEGF) inhibitor injection in unrecognised early pregnancy. 2016 , 34, 650-3		7
107	Anti-VEGF in diabetic retinopathy and diabetic macular edema. 2016 , 11, 443-451		0
106	Electroretinographic evaluations of retinal function before, just after, and after intravitreal injections. 2016 , 6, 31104		2
105	Short-Term Visual Acuity and Intraocular Pressure Changes and Their Correlation after Anti-Vascular Endothelial Growth Factor Injection. 2016 , 236, 36-42		4
104	NONINFECTIOUS VITRITIS AFTER INTRAVITREAL INJECTION OF ANTI-VEGF AGENTS: Variations in Rates and Presentation by Medication. 2016 , 36, 909-13		34
103	[Analysis of cardiovascular diseases after the upload phase with intravitreal ranibizumab and bevacizumab in patients with exudative age-related macular degeneration]. 2016 , 113, 589-95		4
102	Management of iatrogenic crystalline lens injury occurred during intravitreal injection. 2016 , 36, 527-30		5
101	Uveitic Macular Edema: Treatment Update. 2016 , 4, 30-37		18
100	Postinjection Endophthalmitis Rates and Characteristics Following Intravitreal Bevacizumab, Ranibizumab, and Aflibercept. 2016 , 165, 88-93		69
99	Incidence and clinical features of post-injection endophthalmitis according to diagnosis. <i>British Journal of Ophthalmology</i> , 2016 , 100, 1058-61	5.5	37
98	Short-term effects of intravitreal ranibizumab and bevacizumab administration on 24-h ambulatory blood pressure monitoring recordings in normotensive patients with age-related macular degeneration. 2017 , 31, 677-683		7

97	Intravitreal Antiangiogenic Therapy of Uveitic Macular Edema: A Review. 2017 , 33, 235-239	11
96	Topical versus subconjunctival anti-vascular endothelial growth factor therapy (Bevacizumab, Ranibizumab and Aflibercept) for treatment of corneal neovascularization. 2017 , 31, 99-105	17
95	A Systematic Review. 2017 , 156, 435-441	13
94	Effect of intravitreal ranibizumab on the ocular circulation of the untreated fellow eye. 2017 , 255, 1543-1550	8
93	TOPICAL APRACLONIDINE REDUCES PAIN AFTER INTRAVITREAL INJECTIONS: A Double-Blind Randomized Controlled Trial. 2017 , 37, 1575-1580	5
92	Chitosan-coated PLGA nanoparticles of bevacizumab as novel drug delivery to target retina: optimization, characterization, and in vitro toxicity evaluation. 2017 , 45, 1397-1407	60
91	Evaluation of effect of bevacizumab on central subfield macular thickness in the injected and contralateral (untreated) eye of patients with bilateral diabetic macular oedema. 2017 , 2, e000102	3
90	Therapeutic approaches for corneal neovascularization. 2017 , 4, 28	42
89	Full-thickness Macular Hole after Intravitreal Aflibercept Injection in a Patient with Wet Age-related Macular Degeneration. 2017 , 58, 875	2
88	Mortality associated with bevacizumab intravitreal injections in age-related macular degeneration patients after acute myocardial infarct: a retrospective population-based survival analysis. 2018 , 256, 651-663	17
87	Peripheral Ulcerative Keratitis Associated with Granulomatosis with Polyangiitis Emerging Despite Cyclophosphamide, Successfully Treated with Rituximab. 2018 , 57, 1783-1788	8
86	Characterization and Pharmacokinetics of Triamcinolone Acetonide-Loaded Liposomes Topical Formulations for Vitreoretinal Drug Delivery. 2018 , 34, 416-425	27
85	EFFECTS OF INTRAVITREAL RANIBIZUMAB AND BEVACIZUMAB ON THE RETINAL VESSEL SIZE IN DIABETIC MACULAR EDEMA. 2018 , 38, 1120-1126	9
84	Pathophysiology, screening and treatment of ROP: A multi-disciplinary perspective. 2018 , 62, 77-119	60
83	Incidence and Outcomes of Infectious and Noninfectious Endophthalmitis after Intravitreal Injections for Age-Related Macular Degeneration. 2018 , 125, 66-74	49
82	Drug-induced uveitis. 2018 , 29, 588-603	39
81	[Embolic stroke immediately after initial administration of intravitreal aflibercept]. 2018 , 58, 314-319	2
80	Therapeutic Effects of a Novel Phenylphthalimide Analog for Corneal Neovascularization and Retinal Vascular Leakage. 2018 , 59, 3630-3642	7

79	Risk factors for breakthrough vitreous hemorrhage after intravitreal anti-VEGF injection in age-related macular degeneration with submacular hemorrhage. 2018 , 8, 10560	9
78	Real-World Safety of Intravitreal Bevacizumab and Ranibizumab Treatments for Retinal Diseases in Thailand: A Prospective Observational Study. 2018 , 38, 853-865	8
77	Antibiotic prophylaxis for preventing endophthalmitis after intravitreal injection: a systematic review. 2018 , 32, 1423-1431	14
76	[Importance of vitrectomy in endophthalmitis : How immediate vitrectomy can restore visual acuity]. 2019 , 116, 569-571	3
75	Anti-VEGF-Aptamer Modified C-Dots-A Hybrid Nanocomposite for Topical Treatment of Ocular Vascular Disorders. 2019 , 15, e1902776	33
74	Expression of vascular infarction-related molecules after anti-vascular endothelium growth factor treatment for diabetic macular edema. 2019 , 9, 12373	3
73	Novel Triamcinolone Acetonide-Loaded Liposomal Topical Formulation Improves Contrast Sensitivity Outcome After Femtosecond Laser-Assisted Cataract Surgery. 2019 , 35, 512-521	8
72	Rhegmatogenous Retinal Detachment after Intravitreal Injection of Anti-Vascular Endothelial Growth Factor. 2019 , 126, 1424-1431	27
71	Lessons Learned From Avastin and OCT-The Great, the Good, the Bad, and the Ugly: The LXXV Edward Jackson Memorial Lecture. 2019 , 204, 26-45	6
70	Novel Triamcinolone Acetonide-Loaded Liposomes Topical Formulation for the Treatment of Cystoid Macular Edema After Cataract Surgery: A Pilot Study. 2019 , 35, 106-115	13
69	Intraocular chemotherapy for vitreoretinal lymphoma: A review. 2020 , 48, 240-248	15
68	REDUCTION OF POSTINTRAVITREAL INJECTION PAIN USING ICE: An Open-Label Interventional Randomized Controlled Trial. 2020 , 40, 1434-1438	2
67	Meta-herpetic ulcer following intravitreal bevacizumab. 2020 , 1120672120952035	1
66	Conserved regression patterns of retinopathy of prematurity after intravitreal ranibizumab: A class effect. 2021 , 31, 2135-2140	1
65	Topical Triamcinolone Acetonide-Loaded Liposomes as Primary Therapy for Macular Edema Secondary to Branch Retinal Vein Occlusion: A Pilot Study. 2020 , 36, 393-403	5
64	Alone laser versus bevacizumab plus laser for diffuse diabetic macular edema (ALBA randomized trial). 2021 , 13, 2515841420988210	
63	Pseudophakic Cystoid Macular Oedema. 2021 , 173-189	1
62	Incidence and Factors of Postoperative Lens Opacity after Lens-Sparing Vitrectomy for Retinopathy of Prematurity. <i>Ophthalmology Retina</i> , 2021 , 5, 1139-1145	3.8 0

61	Safety and Tolerability of Topical Ophthalmic Triamcinolone Acetonide-Loaded Liposomes Formulation and Evaluation of Its Biologic Activity in Patients with Diabetic Macular Edema. 2021 , 13,		5
60	Effect of intravitreal bevacizumab in the uninjected fellow eye of patients treated for retinal disorders. 2021 , 7, 234-239		
59	Increased mortality after intravitreal injections of anti-VEGF for neovascular AMD among patients with prior stroke or acute myocardial infarction. 2021 ,		1
58	Primary vitreoretinal lymphoma: a diagnostic and management challenge. 2021 , 138, 1519-1534		7
57	Role of bevacizumab intraocular injection in the management of neovascular glaucoma. <i>International Journal of Ophthalmology</i> , 2021 , 14, 855-859	1.4	
56	Intravitreal Injection Therapy: Current Techniques and Supplemental Services. 2021 , 5, 438-447		
55	Intravitreal Injections: Techniques and Sequelae. 2007 , 67-87		3
54	Treatment of choroidal neovascularization using intravitreal bevacizumab. 2007 , 85, 526-534		43
53	Acute retinal arterial occlusion after intravenous administration of bevacizumab. <i>BMJ Case Reports</i> , 2009 , 2009,	0.9	2
52	Self-limited membranous nephropathy after intravitreal bevacizumab therapy for age-related macular degeneration. 2017 , 6, 134-137		10
51	Infectious and sterile endophthalmitis after intravitreal injections: differential diagnosis, prevention, treatment. 2017 , 10, 62-69		4
50	Anti-VEGF Treatment in Corneal Diseases. 2020 , 21, 1159-1180		9
49	The treatment of wet age-related macular degeneration. 2009 , 106, 312-7		16
48	Confluent diode laser coagulation: the gold standard of therapy for retinopathy of prematurity. 2015 , 52, 43-51		4
47	Bilateral Total Cataract After Intravitreal Bevacizumab Injection in Aggressive Posterior Retinopathy of Prematurity. 2019 , 56, e28-e30		7
46	Safety and efficacy of intravitreal bevacizumab followed by pegaptanib maintenance as a treatment regimen for age-related macular degeneration. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2006 , 37, 446-54	1.4	25
45	Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2007 , 38, 233-7	1.4	106
44	Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2009 , 40, 293-5	1.4	88

43	Ghost cell glaucoma after intravitreal bevacizumab for postoperative vitreous hemorrhage following vitrectomy for proliferative diabetic retinopathy. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2010 , 41, 72-7	1.4	7
42	Full Thickness Macular Hole Formation in a Patient with Cystoid Macular Edema Caused by CRVO Treated with Intravitreal Bevacizumab. 2010 , 1-4		3
41	Association between systemic anticoagulation and rate of intraocular hemorrhage following intravitreal anti-VEGF therapy for age-related macular degeneration. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2013 , 44, 455-9	1.4	9
40	Ocular hypertension and intraocular pressure asymmetry after intravitreal injection of anti-vascular endothelial growth factor agents. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2013 , 44, 460-4	1.4	27
39	Comparison of intravitreal bevacizumab with macular photocoagulation for treatment of diabetic macular edema: a systemic review and Meta-analysis. <i>International Journal of Ophthalmology</i> , 2014 , 7, 1048-55	1.4	6
38	Comparison of intravitreal bevacizumab with intravitreal triamcinolone acetonide for treatment of cystoid macular edema secondary to retinal vein occlusion: a Meta-analysis. <i>International Journal of Ophthalmology</i> , 2015 , 8, 1234-9	1.4	7
37	Bevacizumab: off-label use in ophthalmology. <i>Indian Journal of Ophthalmology</i> , 2007 , 55, 417-20	1.6	47
36	Safety and cost-effectiveness of single dose dispensing of bevacizumab for various retinal pathologies in developing countries. <i>Indian Journal of Ophthalmology</i> , 2007 , 55, 488-90	1.6	8
35	Idiopathic choroidal neovascular membrane in a young female. <i>Oman Journal of Ophthalmology</i> , 2009 , 2, 133-6	0.7	3
34	Real-world evidence of safety profile of intravitreal bevacizumab (Avastin) in an Indian scenario. <i>Indian Journal of Ophthalmology</i> , 2017 , 65, 596-602	1.6	12
33	Breaking down the Barrier: Topical Liposomes as Nanocarriers for Drug Delivery into the Posterior Segment of the Eyeball.		4
32	Seguridad sistémica del tratamiento anti-VEGF. 2010 , 155-161		
31	Seguridad ocular del tratamiento anti-VEGF. 2010 , 145-154		
30	Visual loss from hyphema following intravitreal bevacizumab. <i>BMJ Case Reports</i> , 2010 , 2010,	0.9	
29	Anti-VEGF-Therapie aus kardiologischer Sicht. 2011 , 131-142		
28	A minimally invasive jet injector for intravitreal and subconjunctival injection. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2012 , 43, 57-62	1.4	2
27	Ranibizumab. 2014 , 335-350		
26	Finding New Partnerships: The Function of Individual Extracellular Receptor Domains in Angiogenic Signalling by VEGF Receptors. 2014 , 47-75		

25	Drug-Induced Uveitis. 2016 , 1561-1574		
24	The short-needle intravitreal injection technique. <i>International Journal of Ophthalmology</i> , 2016 , 9, 929-304		2
23	Medical Management of CME Associated with Uveitis. 2017 , 59-75		
22	Safety Considerations of Pharmacotherapy. 2017 , 239-256		
21	Outcome of Cataract Surgery in Patients Treated for Retinopathy of Prematurity. <i>Open Journal of Ophthalmology</i> , 2017 , 07, 293-302	0.2	3
20	Intravitreal Ranibizumab/ Lucentis (IVTL) injections in Glaucoma patients-Intraocular Pressure (IOP) elevation and the use of Anterior Chamber Paracentesis (ACP). 2017 , 1, 033-041		
19	The Role of Optical Coherence Tomography in Anti-Vascular Endothelial Growth Factor Therapies. 2009 , 279-288		
18	The international intravitreal bevacizumab safety survey. <i>British Journal of Ophthalmology</i> , 2006 , 90, 1440-1	5.5	5
17	Skin rash associated with intravitreal bevacizumab in a patient with macular choroidal neovascularization. <i>Clinical Ophthalmology</i> , 2009 , 3, 129-31	2.5	8
16	Inhibition of choroidal neovascularization by topical application of angiogenesis inhibitor vasostatin. <i>Molecular Vision</i> , 2009 , 15, 1897-905	2.3	10
15	Effects of rat anti-VEGF antibody in a rat model of corneal graft rejection by topical and subconjunctival routes. <i>Molecular Vision</i> , 2011 , 17, 104-12	2.3	23
14	Delayed corneal epithelial healing after intravitreal bevacizumab: a clinical and experimental study. <i>Journal of Ophthalmic and Vision Research</i> , 2011 , 6, 18-25	1.2	7
13	Therapeutic potential of intravitreal pharmacotherapy in retinal vein occlusion. <i>International Journal of Ophthalmology</i> , 2012 , 5, 759-70	1.4	5
12	Two Different Doses of Intravitreal Bevacizumab for Treatment of Choroidal Neovascularization Associated with Age-related Macular Degeneration. <i>Journal of Ophthalmic and Vision Research</i> , 2008 , 3, 102-7	1.2	4
11	Optical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis). <i>Transactions of the American Ophthalmological Society</i> , 2014 , 112, 160-98		20
10	Evaluating the safety of intracameral bevacizumab application using oxidative stress and apoptotic parameters in corneal tissue. <i>International Journal of Ophthalmology</i> , 2015 , 8, 697-702	1.4	4
9	Intravitreal Injection of Bevacizumab: Review of our previous Experience. <i>Iranian Journal of Pharmaceutical Research</i> , 2018 , 17, 1093-1098	1.1	4
8	Results of Intravitreal Anti-Vascular Endothelial Growth Factor Therapy in Inflammatory Choroidal Neovascularization. <i>Journal of Current Ophthalmology</i> , 2021 , 33, 68-74		2

7	Cataract Associated with ROP and Other Retinal Pathologies. 2022 , 189-205		
6	Cataract in retinopathy of prematurity - A review.. <i>Indian Journal of Ophthalmology</i> , 2022 , 70, 369-377	1.6	1
5	Accuracy of intravitreal injection volume for aflibercept pre-filled syringe and BD Luer-Lok one-milliliter syringe.. <i>International Journal of Retina and Vitreous</i> , 2022 , 8, 27	2.9	0
4	Survey of Intravitreal Injection Techniques and Treatment Protocols Among Members of the Turkish Ophthalmological Association.. <i>Türk Oftalmoloji Dergisi</i> , 2021 , 51, 373-380	1.2	0
3	Incidence, Risk Factors and Outcomes of Rhegmatogenous Retinal Detachment after Intravitreal Injections of Anti-Vascular Endothelial Growth Factor for Retinal Diseases: Data from the Fight Retinal Blindness! Registry.. <i>Ophthalmology Retina</i> , 2022 ,	3.8	
2	Review of Intraocular Inflammation After Antivascular Endothelial Growth Factor Agents. <i>International Ophthalmology Clinics</i> , 2022 , 62, 35-47	1.7	0
1	Temporal fluctuations of cardiovascular parameters after intravitreal injections. 2022 , 85, 1088-1092		0